myirislogo
30 March, 2015 19:41 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Ntpc 147.50 1.24
I T C 327.90 3.41
State Bank O 267.90 1.65
Icici Bank 318.35 1.26
Tata Stl 322.40 2.35
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Glenmark Pharmaceutical Limited
Glenmark Pharmaceutical Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:532296NSE:GLENMARKBloomberg:GNP@INReuters:GLEN.BO
Market Lot: 1Face Value: 1ISIN Demat: INE935A01035
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
12-MAR-15 Glenmark Pharmaceutical (Glenmark), a manufacturer of generic formulation products and API, announced today that it has received approval for Salmecort (Salmeterol + Fluticasone) MDI inhaler, from the Ministry of Health, Russia. 26-FEB-15 Glenmark Pharmaceutical (Glenmark), a manufacturer of generic formulation products and API, announced the U.S. market approval and introduction of Trandolapril & Verapamil Hydrochloride (HCI) Exten...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Glenmark receives approval for Salmecort in Russia  -IRIS 12-Mar-15
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2014 (12)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 22735.5719352.8815468.16
Other Income671.341162.45551.04
Total Income23406.9120515.3316019.20
Cost of goods sold18049.3616168.6012536.90
OPBDIT5357.554346.733482.30
PAT4338.243861.072652.99
Gross Block---
Equity capital271.22270.85270.53
EPS (Rs.)16.0114.269.81
DPS (Rs.)---
BV (Rs.)---
P/E range (x)28.97 - 38.2321.11 - 38.6326.78 - 35.80
Debt / Equity (x)---
Operating margin (% of OI)22.921.221.7
Net margin (% of OI)18.518.816.6
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
B/ 2, Mahalaxmi Chambers
22, Bhulabhai Desai Road
Mumbai
Maharashtra-400 026
PHONE
- - -
FAX
- - -
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer